Across TCGA pan-cancer cohorts, TMEM80 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM80 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM80 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM80 expression acts as an unfavorable survival marker.
HNSC and CESC are the cancer types where TMEM80 Mutation most reproducibly stratifies survival.